The global Fabry disease treatment market size was USD 1.81 Billion in 2020 and is projected to reach USD 3.85 Billion by 2028, expanding at a CAGR of 9.3 % during the forecast period, 2021–2028. The growth of the market is attributed to increasing incidence of the disease coupled with increasing adoption of novel therapies such, as chaperone treatment.
Fabry disease is an X-linked lysosomal storage illness that causes progressive organ failure due to lack of the alpha-galactosidase enzyme. An abnormal buildup of a specific fatty substance named globotriaosylceramide in numerous human tissues, including eyes, skin, kidneys, gastrointestinal tract, brain, heart, and central nervous system, causes this condition. Patients with Fabry disease can have impaired kidney function that can lead to full renal failure, early heart condition, and disabling gastrointestinal symptoms. As there is no cure for Fabry disease, treatment focuses on preventing complications and alleviating symptoms.
Enzyme replacement therapy (ERT), chaperone therapy, and substrate reduction therapy are some of the current treatments. There were no viable treatments for Fabry before enzyme replacement therapy, and the typical life expectancy of a Fabry patient was up to 50 years old. The disease's late onset and mild symptoms leads to number of patients undiagnosed. Sanofi estimates that approximately 3,000 patients in the US suffer from Fabry disease Patients with Fabry disease live longer lives on average than patients with other lysosomal storage disorders.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing R&D activities and the potential approval of promising pipeline drugs such as substrate reduction therapies and enzyme replacement therapies are expected to propel the market during the period.
- Rising strategic collaboration and licensing agreement between the companies is expected to fuel the market growth during the forecast period.
- The preference for substrate reduction therapies and gene therapies in the healthcare industry is expected to drive the growth of the industry players in the projected timeline.
- Growing emergence of drugs used in the treatment of the risk associated with Fabry disease is anticipated to spur the market growth during the forecast period.
- Effective treatment is either unavailable or unaffordable, which can hamper the market growth.
- Extensive R&D activities and potential approval of promising pipeline products such as substrate reduction therapies and enzyme replacement therapies are projected to fuel the market expansion in coming years.
Key Players
- Sanofi S.A.
- Shire Plc.
- Amicus Therapeutics Inc.
- ISU Abxis Co Ltd.
- JCR Pharmaceuticals Co Ltd.
- Protalix Biotherapeutics Inc.
- Idorsia Pharmaceuticals Ltd.
- Avrobio Inc.
- Greenovation Biotech GmbH
- Moderna Therapeutics Inc.
- Green Cross Pharma Pte Ltd.
Competitive Landscape
Key players competing in the Fabry disease treatment market include Sanofi S.A., Shire Plc., Amicus Therapeutics Inc., ISU Abxis Co Ltd., JCR Pharmaceuticals Co Ltd., Protalix Biotherapeutics Inc., Idorsia Pharmaceuticals Ltd., Avrobio Inc., Greenovation Biotech GmbH, Moderna Therapeutics Inc., and Green Cross Pharma Pte Ltd.
Sanofi’s sales of medicine Fabrazyme is helping the company to account for a major market share. During the forecast period, Sanofi and Shire are expected to encounter significant competition from biosimilar releases.
Meanwhile, Amicus Therapeutics’s Galafold, the first oral treatment for Fabry disease, is aiding the company to become a major player in the rare disease space. On the other hand, Idorsia and Avrobio are expected to command a large share of the market with their drug lucerastat and AVR-RD-01, respectively.
To Get a New Sample Request:
https://growthmarketreports.com/request-sample/2002
Contact Us
- Growth Market Reports
- Phone: +1 909 414 1393
- Email: sales@growthmarketreports.com
- Web: https://growthmarketreports.com
